Darlene Barnard

1.8k total citations
20 papers, 1.5k citations indexed

About

Darlene Barnard is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Darlene Barnard has authored 20 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 7 papers in Oncology and 4 papers in Cell Biology. Recurrent topics in Darlene Barnard's work include Protein Kinase Regulation and GTPase Signaling (9 papers), DNA Repair Mechanisms (6 papers) and Melanoma and MAPK Pathways (6 papers). Darlene Barnard is often cited by papers focused on Protein Kinase Regulation and GTPase Signaling (9 papers), DNA Repair Mechanisms (6 papers) and Melanoma and MAPK Pathways (6 papers). Darlene Barnard collaborates with scholars based in United States, Germany and Spain. Darlene Barnard's co-authors include Mark S. Marshall, Bruce Diaz, Alastair J. King, Wenyan Miao, Huaiyu Sun, Shubha Bagrodia, Ellen Chuang, Joseph Avruch, Michele Yip-Schneider and Amy E. Lin and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Molecular and Cellular Biology.

In The Last Decade

Darlene Barnard

20 papers receiving 1.5k citations

Peers

Darlene Barnard
Bruce Diaz United States
Valerie L. Goss United States
Daniel A. Ritt United States
Pamela Das United Kingdom
Erik Wilker United States
Anthony Makkinje United States
R. Lyall United States
Keisuke Taniuchi Japan
Yunchao Chang United States
Christine Dozier France
Bruce Diaz United States
Darlene Barnard
Citations per year, relative to Darlene Barnard Darlene Barnard (= 1×) peers Bruce Diaz

Countries citing papers authored by Darlene Barnard

Since Specialization
Citations

This map shows the geographic impact of Darlene Barnard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Darlene Barnard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Darlene Barnard more than expected).

Fields of papers citing papers by Darlene Barnard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Darlene Barnard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Darlene Barnard. The network helps show where Darlene Barnard may publish in the future.

Co-authorship network of co-authors of Darlene Barnard

This figure shows the co-authorship network connecting the top 25 collaborators of Darlene Barnard. A scholar is included among the top collaborators of Darlene Barnard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Darlene Barnard. Darlene Barnard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
King, Constance, Samuel McNeely, Darlene Barnard, et al.. (2015). LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms. Molecular Cancer Therapeutics. 14(9). 2004–2013. 139 indexed citations
2.
Barnard, Darlene, Teresa F. Burke, Gregory P. Donoho, et al.. (2015). LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models. Investigational New Drugs. 34(1). 49–60. 19 indexed citations
3.
Calvo, Emiliano, Victor J. Chen, Mark S. Marshall, et al.. (2014). Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer. Investigational New Drugs. 32(5). 955–968. 47 indexed citations
4.
King, Constance, Darlene Barnard, David A. Barda, et al.. (2013). Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Investigational New Drugs. 32(2). 213–226. 90 indexed citations
5.
Peek, Victoria L., Suzane L. Um, S. Betty Yan, et al.. (2011). Abstract A49: Circulating tumor cell (CTC) assay development for detection of H2AX as a clinical pharmacodynamic (PD) marker for Chk1 kinase inhibitors.. Molecular Cancer Therapeutics. 10(11_Supplement). A49–A49. 1 indexed citations
6.
McNeely, Samuel, Teresa F. Burke, Darlene Barnard, et al.. (2011). Abstract A108: LY2606368, a second generation Chk1 inhibitor, inhibits growth of ovarian carcinoma xenografts either as monotherapy or in combination with standard-of-care agents.. Molecular Cancer Therapeutics. 10(11_Supplement). A108–A108. 6 indexed citations
7.
Marshall, Mhairi, et al.. (2010). 194 Characterization and preclinical development of LY2606368, a second generation Chk1 inhibitor. European Journal of Cancer Supplements. 8(7). 65–65. 1 indexed citations
8.
Marshall, Mark S., David A. Barda, Darlene Barnard, et al.. (2009). Abstract B248: Characterization and preclinical development of LCI-1, a selective and potent Chk1 inhibitor in phase 1 clinical trials. Molecular Cancer Therapeutics. 8(12_Supplement). B248–B248. 4 indexed citations
9.
Sweeney, Christopher J., Mark S. Marshall, Darlene Barnard, et al.. (2002). Cyclo-oxygenase-2 expression in primary cancers of the lung and bladder compared to normal adjacent tissue. Cancer Detection and Prevention. 26(3). 238–244. 15 indexed citations
10.
Yip-Schneider, Michele, Wenyan Miao, Amy E. Lin, et al.. (2000). Regulation of the Raf-1 kinase domain by phosphorylation and 14-3-3 association. Biochemical Journal. 351(1). 151–151. 74 indexed citations
11.
Yip-Schneider, Michele, Wenyan Miao, Amy E. Lin, et al.. (2000). Regulation of the Raf-1 kinase domain by phosphorylation and 14-3-3 association. Biochemical Journal. 351(1). 151–159. 60 indexed citations
12.
Yip-Schneider, Michele, Amy E. Lin, Darlene Barnard, Christopher J. Sweeney, & Mark S. Marshall. (1999). Lack of elevated MAP kinase (Erk) activity in pancreatic carcinomas despite oncogenic K-ras expression.. International Journal of Oncology. 15(2). 271–9. 62 indexed citations
13.
Barnard, Darlene, et al.. (1998). In VitroInhibition of Ras–Raf Association by Short Peptides. Biochemical and Biophysical Research Communications. 247(1). 176–180. 37 indexed citations
14.
Barnard, Darlene, Bruce Diaz, David K. Clawson, & Mark S. Marshall. (1998). Oncogenes, growth factors and phorbol esters regulate Raf-1 through common mechanisms. Oncogene. 17(12). 1539–1547. 69 indexed citations
15.
King, Alastair J., Huaiyu Sun, Bruce Diaz, et al.. (1998). The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338. Nature. 396(6707). 180–183. 363 indexed citations
16.
Diaz, Bruce, Darlene Barnard, Adele J. Filson, et al.. (1997). Phosphorylation of Raf-1 Serine 338-Serine 339 Is an Essential Regulatory Event for Ras-Dependent Activation and Biological Signaling. Molecular and Cellular Biology. 17(8). 4509–4516. 175 indexed citations
17.
Schweitzer, Mary H., Mark S. Marshall, Keith T. Carron, et al.. (1997). Heme compounds in dinosaur trabecular bone. Proceedings of the National Academy of Sciences. 94(12). 6291–6296. 66 indexed citations
18.
Barnard, Darlene, et al.. (1995). Identification of the sites of interaction between c-Raf-1 and Ras-GTP.. PubMed. 10(7). 1283–90. 51 indexed citations
19.
Chuang, Ellen, et al.. (1994). Critical Binding and Regulatory Interactions between Ras and Raf Occur through a Small, Stable N-Terminal Domain of Raf and Specific Ras Effector Residues. Molecular and Cellular Biology. 14(8). 5318–5325. 39 indexed citations
20.
Chuang, Ellen, et al.. (1994). Critical binding and regulatory interactions between Ras and Raf occur through a small, stable N-terminal domain of Raf and specific Ras effector residues.. Molecular and Cellular Biology. 14(8). 5318–5325. 153 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bruce Diaz Breakdown of academic impact, for papers by Valerie L. Goss Breakdown of academic impact, for papers by Daniel A. Ritt Breakdown of academic impact, for papers by Pamela Das Breakdown of academic impact, for papers by Erik Wilker Breakdown of academic impact, for papers by Anthony Makkinje Breakdown of academic impact, for papers by R. Lyall Breakdown of academic impact, for papers by Keisuke Taniuchi Breakdown of academic impact, for papers by Yunchao Chang Breakdown of academic impact, for papers by Christine Dozier
Rankless by CCL
2026